NoToVir is a new biotech Start-up established on December 2017, active in the field of medical biotechnology. The company's main objective is the screening and characterization of innovative antiviral molecules for the production of new pharmacologically selectively active principles against viral infections.
The invention underlying the first internationally extended patent relies on the characterization of the host cell proteins that are subjected to a specific post-translational modification (PTM) process during Herpesvirus infection, known as citrullination. The team has recently shown that during the Herpesvirus infection (ie HSV-1, HSV-2 or HCMV) the cellular enzymes responsible for this PTM are indeed activated, and citrullination of many cellular proteins is actually induced. Furthermore, the citrullination process seems to be essential for the replication of Herpesvirus: by blocking the activity of the cellular enzymes inducing citrullination, the mechanism of viral replicatio...
NoToVir is a new biotech Start-up established on December 2017, active in the field of medical biotechnology. The company's main objective is the screening and characterization of innovative antiviral molecules for the production of new pharmacologically selectively active principles against viral infections.
The invention underlying the first internationally extended patent relies on the characterization of the host cell proteins that are subjected to a specific post-translational modification (PTM) process during Herpesvirus infection, known as citrullination. The team has recently shown that during the Herpesvirus infection (ie HSV-1, HSV-2 or HCMV) the cellular enzymes responsible for this PTM are indeed activated, and citrullination of many cellular proteins is actually induced. Furthermore, the citrullination process seems to be essential for the replication of Herpesvirus: by blocking the activity of the cellular enzymes inducing citrullination, the mechanism of viral replication is also completely blocked. The proposed therapeutic approach is innovative, specific and potentially less toxic than those currently in use. Our recent data on a small cohort of cytomegalovirus-infected animals corroborate the data so far obtained in vitro.
The invention underlying the second patent relies on a different group of natural molecules derived from plant roots (strigolactones) and their synthesis-derived homologs. These molecules exert a strong antiviral activity against Herpes simplex type 1 (HSV-1) and type 2 (HSV-2). The molecular mechanisms these molecules rely on to inhibit HSV-1 and -2 replication are under investigation, but the data so far obtained in vitro suggest that these molecules can be further exploited for the prophylaxis or treatment of recurrent labial and genital infections due to Herpes simplex infections.
Moreover, in line with our R&D mission and founded on the experience and work carried out over the years in the Academia (Laboratory of Pathogenesis of Viral Infections, Department of Public Health and Pediatric, University of Turin, and Laboratory of Virology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy) at NoToVir we are continuously looking for and testing new potentially active antiviral molecules.
More information

Employees

Gloria Griffante
Admin
Gloria Griffante Biotechnologist
Marco De Andrea
Admin
Marco De Andrea CTO MD, PhD. Associate Professor of Medical Microbiology, University of Turin - Medical School
Matteo Biolatti
Admin
Matteo Biolatti Lab Coordinator and Responsible for in vitro infection models